Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Details (Tables)

3 Months Ended

Mar. 31, 2024

	March 31,		December 31,
	2024		2023
Prepaid expenses and other current assets:
Prepaid insurance	$	255,020	$	426,413
Prepaid research and development costs		92,899		91,232
Prepaid other and other current assets		98,156		22,854
Total prepaid expenses and other current assets	$	446,075	$	540,499

Accrued and other current liabilities:
Accrued research and development costs	$	282,876	$	40,596
Accrued compensation and benefits		230,815		716,490
Accrued other		35,529		502
Total accrued and other current liabilities	$	549,220	$	757,588